Erbitux improves first line Head and Neck Cancer Survival (NEJM)

Imclone and BMS have announced the publication of  Phase III results of Erbitux (cetuximab) plus platinum-based chemotherapy in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Inspire to initiate Phase I for Rho kinase inhibitor INS117548 in Glaucoma

Inspire Pharmaceuticals have announced that it will shortly commence a Phase I clinical trial of INS117548 Ophthalmic Solution for the treatment of glaucoma